BlackRock Health Sciences Opps Inv C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
BlackRock Health Sciences Opportunities Portfolio Investor C Shares SHSCX
- NAV / 1-Day Return $49.51 / −0.22 %
- Fund Size $6.4B
- Adjusted Expense Ratio 1.900%
- Net Expense Ratio 1.890%
- Fee Level: Distribution Below Average
- Share Class Type Level Load
- Morningstar Category Health
- Equity Style Box (Funds) Large Value
- Minimum Initial Investment $1,000
- Investment Status Open
- TTM Yield 0.00%
- Turnover Ratio 49%
Morningstar’s Analysis SHSCX
Will SHSCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 54.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 12.13 | 760M | Healthcare |
Johnson & Johnson | 8.13 | 510M | Healthcare |
Merck & Co Inc | 5.57 | 349M | Healthcare |
AbbVie Inc | 5.27 | 330M | Healthcare |
Thermo Fisher Scientific Inc | 4.91 | 308M | Healthcare |
Gilead Sciences Inc | 4.24 | 266M | Healthcare |
Amgen Inc | 3.97 | 249M | Healthcare |
UnitedHealth Group Inc | 3.89 | 244M | Healthcare |
Danaher Corp | 3.50 | 219M | Healthcare |
Vertex Pharmaceuticals Inc | 3.26 | 204M | Healthcare |